BRCA‑P: An international randomised phase III study evaluating the RANK ligand inhibitor denosumab for the prevention of breast cancer in BRCA1 mutation carriers [2018–2022] - Francis, P; Singer, C; Saunders, C (2018)
; last access: 02.04.2018